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Changes in Renal Function after Different Tandem Hematopoietic 
Stem-cell Transplantation Approaches in Patients with Multiple 
Myeloma
This study was done to observe the alteration of the estimated glomerular filtration rate 
(eGFR) in multiple myeloma patients according to type of tandem hematopoietic stem cell 
transplantation (HSCT). Forty-one patients were enrolled in this study. Twenty patients 
underwent autologous HSCT (auto-HSCT) and 21 patients underwent allogeneic HSCT (allo-
HSCT). The changes in eGFR after the two tandem HSCT modalities were different between 
the two groups, according to the donor of stem cells (P = 0.016). In the auto-HSCT group, 
the eGFR, recorded 12 months after secondary HSCT, was significantly decreased compared 
with the eGFR recorded before stem cell mobilization (P = 0.005). Although there was no 
significant difference, the trend showed that the eGFR after allo-HSCT decreased from the 
previous HSCT until a month after secondary HSCT. In addition, after 6 months of 
secondary HSCT, the eGFR recovered to the level recorded prior to the HSCT (P = 0.062). 
This difference may be due to total body irradiation, a calcineurin inhibitor, or 
maintemance therapy. Changes in renal function would be monitored closely for these 
patients. The recovery of the eGFR would be a main focus for the patients treated with the 
total body irradiation or the calcineurin inhibitor, a progressive decline of the eGFR would 
be also crucial for the patients treated with maintenance therapy.
Key Words: Multiple Myeloma; Allogeneic Stem-Cell Transplantation; Autologous Stem-
Cell Transplantation; Renal Function; Tandem Transplantation
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INTRODUCTION
Multiple myeloma is a clonal B-cell disease of slowly proliferat-
ing plasma cells, which is accompanied by the production of 
monoclonal proteins and lytic bone lesions (1). Up to half of 
newly diagnosed patients have shown a decrease in creatinine 
clearance and approximately 9% require dialysis because of se-
vere renal impairments (1). Renal failure is contributed by sev-
eral factors including monoclonal light chains, hypercalcemia, 
infection, and hyperuricemia (1). Cast nephropathy is a typical 
renal complication found in myeloma patients.
  Hematopoietic stem-cell transplantation (HSCT) is an effec-
tive therapy for diseases that require strong chemotherapy such 
as hematopoietic malignancies, some solid tumors, and other 
immune disorders. However, renal problems are common after 
HSCT, with a cumulative incidence of an acute kidney injury 
(AKI) and a chronic kidney disease (CKD) holding 30%-50% 
and 17.5%-66% of cases, respectively (2). Renal problems after 
HSCT have been associated with the administration of nephro-
toxic drugs, ischemia, radiation, and graft-versus-host disease 
(GVHD).
  In multiple myeloma, tandem HSCT improves overall sur-
vival compared with single HSCT (3). Tandem HSCT is current-
ly considered a standard option for multiple myeloma patients. 
Depending on the donor of the stem cells, tandem HSCT con-
sists of autologous tandem HSCT (auto-HSCT) or autologous/
allogeneic tandem HSCT (allo-HSCT). Some studies have shown 
that HSCT performed in patients with multiple myeloma re-
versed renal failure (4). However, there are few reports on the 
alteration of an estimated glomerular filtration rate (eGFR) in 
multiple myeloma patients after the two types of tandem HSCT. 
The aim of this study was to evaluate the changes in renal func-
tion after different tandem HSCT approaches in patients with 
multiple myeloma.
MATERIALS AND METHODS
We reviewed the medical records at Seoul and Yeouido St. Mary’s 
Hospital in Korea and identified 138 myeloma patients who had 
undergone high-dose chemotherapy and HSCT between August Kang SH, et al.  •  Renal Function after Tandem HSCT
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1999 and March 2009. For the purpose of ruling out the effect  
of factors associated with changes in renal function, we exclud-
ed subjects who had co-morbid conditions (n = 41) such as di-
abetes or hypertension, who had undergone single HSCT (n =  
41), who had less than 12-month-follow-up or relapse within 
12 months (n = 14), or who had undergone renal replacement 
therapy before HSCT (n = 1). Therefore, 41 patients were enrolled 
in this study. AKI following HSCT was defined as  ≥ 2-fold in-
crease in serum creatinine within 100 days (5). All patients in 
this study did not develop AKI during transplantation.
  Peripheral stem cells were mobilized and collected after the 
administration of granulocyte colony-stimulating factor (G-CSF) 
and cyclophosphamide (2 g/m
2). For the first autologous HSCT, 
patients received melphalan (90-100 mg/m
2/day for 2 days). The 
second HSCT was scheduled within 4-10 months. According to 
the donor of the stem cells, patients were divided into auto-HSCT 
and allo-HSCT groups. The followings clinical and laboratory 
data were collected within a month of the date of stem cell mo-
bilization (SCM): gender, any symptom or sign at diagnosis, im-
munoglobulin type, time from diagnosis to HSCT, chemothera-
py regimens prior to HSCT, body mass index, serum creatinine, 
and an eGFR. The staging at diagnosis was carried out accord-
ing to the Durie/Salon staging system (6). The data collected dur-
ing follow-up included age at HSCT, conditioning regimens for 
HSCT, donor of hematopoietic stem cells, nephrotoxic drugs 
during HSCT, and presence of cytomeglovirus (CMV) infection 
and GVHD. All patients who underwent allo-HSCT received a 
calcineurin inhibitor after secondary HSCT. Clinicians adjusted 
the calcineurin inhibitor to maintain a trough level (166-333 nM/ 
L in cyclosporine and 12-25 nM/L in tacrolimus). They were ta-
pered according to the clinical settings. An eGFR was measured 
before the first HSCT, a month after the first HSCT, and 1, 3, 6, 9, 
12, 18, and 24 months after the secondary HSCT. The eGFR was 
calculated using the abbreviated Modification of Diet in Renal 
Disease (MDRD) equation (7). CKD stages were defined accord-
ing to the National Kidney Foundation’s Kidney Disease Out-
comes Quality Initiative guideline (8).
Statistics
The data were analyzed using SPSS version 15 (SPSS Inc., Chi-
cago, IL, USA). Data were presented as means (range) or as counts 
and percentages. For continuous variables, means were com-
pared using an independent t test. Pearson’s chi-squared test or 
Fisher’s exact test were used for categorized variables. We used 
repeated measures ANOVA for the trend in eGFR after HSCT. 
P < 0.05 was considered significant.
Ethics statement
This analysis was approved by institutional review board of Seoul 
St. Mary’s Hospital (KC11RISE0727). Informed consent was waived 
by the board.
RESULTS
Patient characteristics
Twenty patients underwent auto-HSCT and 21 patients under-
went allo-HSCT. Among them, 12 patients had been described 
in previous papers (9, 10). As shown in Table 1, there were no 
significant differences in gender, mean age at HSCT, time from 
diagnosis to transplant, and symptoms and stage at diagnosis. 
Intact immunoglobulin was the most common isotype of im-
munoglobulin in both groups. Chemotherapy regimens prior to 
auto-HSCT were vincristine, doxorubicin and dexamethasone 
(VAD) in eight patients (40%); vincristine, epirubicin and dexa-
methasone (VED) in five patients (25%); bortezomib with dexa-
methasone (VD) in one patient (5%); thalidomide with dexa-
methasone in one patient (5%); bortezomib, doxorubicin and 
dexamethasone (PAD) in one patient (5%); and multiple regi-
Table 1. Characteristics of multiple myeloma patients that underwent hematopoietic 
stem cell transplantation
Characteristics Auto-HSCT Allo-HSCT P value
Number of patients 20 21
Gender (Male)   11 (55%)      10 (47.6%) 0.636
Age at HSCT (yr)  50.4 (40-63)  47.6 (33-59) 0.213
Time from diagnosis to transplant 
   (months)
 8.8 (5-22)  7.9 (5-23) 0.510
Main symptom or sign at diagnosis
   Musculoskeletal pain
   Others
  13 (65%)
    7 (35%)
       7 (33.3%)
     14 (66.6%)
0.058
Stage at diagnosis
   IIIa
   IIIb
   Others
 
  16 (80%)
  1 (5%)
    3 (15%)
 
     16 (76.2%)
    4 (19%)
     1 (4.8%)
0.249
Isotype
   Intact immunoglobulin
   Light chain
 
  16 (80%)
    4 (20%)
 
     15 (71.4%)
       6 (28.6%)
0.815
Chemotherapy regimens prior to HSCT
   Single regimen
   Multiple regimens
   Creatinine before SCM (mg/dL)
 
  16 (80%)
    4 (20%)
0.78  
(0.58-1.05)
 
     16 (76.2%)
       5 (23.8%)
0.81  
(0.56-1.31)
0.768
0.498
eGFR before SCM (mL/min/1.73 m
2) 100.3  
(60.0-137.3)
97.0  
(54.5-124.4)
0.593
Conditioning regimens for HSCT
   Melphalan alone
   Melphalan and fludarabine
   Melphalan, fludarabine, and ATG
 
    20 (100%)
-
-
 
-
     18 (85.7%)
       3 (14.3%)
< 0.001
Total body irradiation   10 (50%)   0 (0%) < 0.001
Nephrotoxic drugs during HSCT
   Aminoglycoside
   Vancomycin
   Amphotericin
  
  16 (80%)
  1 (5%)
   5 (25%)
  
11 (52.4%)
  0 (0%)
     2 (9.5%)
  
0.100
0.488
0.238
Calcineurin inhibitor   0 (0%)     21 (100%) < 0.001
CMV infection during follow-up   1 (5%)        8 (38.1%) 0.020
Maintenance therapy after HSCT   16 (80%)   0 (0%) < 0.001
Data are expressed as numbers (percentages), means (range). auto-HSCT, autologous 
tandem hematopoietic stem-cell transplantation; allo-HSCT, autologous/allogeneic 
tandem hematopoietic stem-cell transplantation; HSCT, hematopoietic stem-cell trans-
plantation; SCM, stem-cell mobilization; eGFR, estimated glomerular filtration rate; 
ATG, antithymocyte globulin; CMV, cytomegalovirus.Kang SH, et al.  •  Renal Function after Tandem HSCT
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mens in four patients (20%). Chemotherapy regimens prior to 
allo-HSCT were VAD in seven patients (33.3%); VED in four pa-
tients (19%); doxorubicin, bortezomib, dexamethasone, and tha-
lidomide (PTAD) in three patients (14.3%); VD in one patient 
(4.8%), PAD in one patient (4.8%); and multiple regimens in five 
patients (23.8%). 
  The levels of plasma creatinine and an eGFR before SCM were 
not significantly different between the two groups. The most 
common conditioning regimen was melphalan and total body 
irradiation (TBI) in auto-HSCT and fludarabine combined with 
melphalan in allo-HSCT. Among the patients who underwent 
auto-HSCT, 10 patients (50%) who received TBI were conditioned 
with 10-12 gray. None of the patients who underwent allo-HSCT 
received TBI. The fraction of patients treated with nephrotoxic 
agents was not significantly different between the two groups. 
Among the 21 patients who underwent allo-HSCT, seven patients 
had acute GVHD (33.3%), and 18 patients had chronic GVHD 
(85.7%). One patient (5%) in the auto-HSCT group and eight pa-
tients (38.1%) in the allo-HSCT group were treated for CMV in-
fection within 1 yr after HSCT. 
  Among the patients who underwent auto-HSCT, 16 patients 
(80%) received maintenance therapy after HSCT. The mainte-
nance therapy was started 3.6 ± 2.8 months after a secondary 
HSCT. The regimens of maintenance therapy were interferon-α 
in three patients (15%); thalidomide in three patients (15%); inter-
feron-α with steroid in three patients (15%); thalidomide with 
steroid and zoledronic acid in three patients (15%); thalidomide 
with steroid in one patient (5%); zoledronic acid with steroid in 
one patient (5%); interferon-α with thalidomide in one paitent 
(5%); and cyclophosphamide with thalidomide and zoledronic 
acid in one patient (5%). None of the patients who underwent 
allo-HSCT received maintenance therapy.
eGFR evolution during the follow-up of HSCT
The changes in eGFR after the two tandem HSCT modalities 
were different between the two groups, according to the donor 
of the stem cells (P = 0.016) (Fig. 1). In the auto-HSCT group, 
the eGFR recorded 12 months after secondary HSCT was sig-
nificantly decreased compared with the eGFR recorded before 
SCM (P = 0.005). Although there was no significant difference, 
the trend showed that the eGFR after allo-HSCT decreased until 
a month after the secondary HSCT. After 6 months of second-
ary HSCT, the eGFR recovered to the level recorded prior to the 
HSCT (P = 0.062).
  Comparing the evolution of renal function in those who re-
ceived TBI and those who did not among the auto-HSCT, the 
trend of the eGFR showed that eGFR in the two groups decreased 
consistently. However, the decrease of the eGFR was higher in 
those who received TBI (before SCM, 106.6 [89.2-137.3] for those 
who received TBI, 94.1 [60.0-123.4] for those who did not; 24 
months after the secondary HSCT, 82.2 [66.3-94.5] for those who 
received TBI, 76.6 [45.0-93.8] for those who did not; P = 0.043). 
In patients who received TBI, the eGFR, recorded 12 months 
after secondary HSCT, was significantly decreased compared 
with the eGFR recorded a month after the secondary HSCT (104.8 
[85.3-117.2] for a month after the secondary HSCT, 87.1 [67.0-
102.8] for 12 months after the secondary HSCT; P = 0.006). Com-
paring the evolution of renal function in those who received the 
maintenance therapy and those who did not among the auto-
HSCT, the changes in eGFR were not significant between the 
two groups (P = 0.443).
  The stages 2 or 3 CKD before HSCT were 5 patients (25%) in 
auto-HSCT and 9 (42.9%) in allo-HSCT. The stages 2 or 3 CKD 
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recorded 6 months after the secondary HSCT were 11 patients 
(55.0%) in auto-HSCT and 16 (76.2%) in allo-HSCT. The stages 
2 or 3 CKD recorded 24 months after the secondary HSCT were 
16 patients (80.0%) in auto-HSCT and 13 (61.9%) in allo-HSCT 
(Fig. 2). In allo-HSCT group, the eGFR of patients with stage IIIb 
at the time of diagnosis was 99.5 (60.6-123.4) before SCM and 
81.9 (56.65-97.43) for 24 months after the secondary HSCT.
 
DISCUSSION
This study shows that the changes in eGFR varied according to 
the donor of HSCT. For the purpose of ruling out the effect of 
factors associated with changes in renal function, we only in-
cluded subjects who did not develop AKI during transplanta-
tion, did not have co-morbid conditions such as diabetes or hy-
pertension, or did not relapse within 12 months. The eGFR re-
corded after auto-HSCT decreased significantly between before 
and 12 months after the secondary HSCT. The eGFR recorded 
after allo-HSCT decreased significantly between before and a 
month after the secondary HSCT. Subsequently, the eGFR of 
this group was maintained during the first 6-month period and 
recovered after 6 months of the secondary HSCT, to the level ob-
served prior to the HSCT.
  Renal impairment is a common feature of multiple myeloma 
(11, 12). Because of the increase in treatment-related toxicity and 
mortality, patients with renal insufficiency are frequently exclud-
ed from HSCT. However, some reports show that HSCT may re-
verse renal impairment in patients with multiple myeloma and 
the prognosis of patients with HSCT is not different from that of 
patients without renal involvement (4, 13). Nevertheless, previ-
ous studies have not addressed the changes in an eGFR accord-
ing to the type of tandem HSCT. This study reported the evalua-
tion of the continuous changes of the eGFR after different tan-
dem HSCT approaches.
  In this study, stage IIIa was the most common stage at the time 
of diagnosis. Intact immunoglobulin, especially IgG, accounted 
for 75.6% of cases. These results are similar to those reported pre-
viously (14, 15). Regarding drug regimens, VAD was the regimen 
used most commonly to induce remission of multiple myeloma. 
Bortezomib with or without dexamethasone was the most com-
mon first regimen for non-responder. Patients with very good 
partial remission or complete remission underwent HSCT.
  The classification of the patients into two groups based on the 
donor of the stem cells revealed that the pattern of changes in an 
eGFR was quite different. The eGFR after auto-HSCT decreased 
slowly until 12 months after the secondary HSCT. It is assumed 
that the decline of eGFR may be due to the administration of 
nephrotoxic drugs. Patient survival or relapse-free survival rate 
in recipients of auto-HSCT was inferior to that observed in recip-
ients of allo-HSCT (16). Many studies have shown that a main-
tenance treatment after auto-HSCT improves patient survival 
or relapse-free survival (17). Therefore, most patients who un-
derwent auto-HSCT received maintenance therapy in this study. 
Interferon-α, thalidomide, and zoledronic acid are the main drugs 
of choice for the maintenance treatment (18, 19). Interestingly, 
in this study, patients in the auto-HSCT group exhibited a sig-
nificant decrease in eGFR 12 months after the secondary HSCT 
compared with patients in the allo-HSCT group. It is now well 
known that the kidney is the main site for interferon degrada-
tion (20). In addition, many cases of renal dysfunction in patients 
treated with zoledronic acid have been reported, although, to 
date, thalidomide pharmacokinetics has rarely been studied in 
patients with renal dysfunction (21, 22). A recent report dem-
onstrated that multiple myeloma patients receiving zoledronic 
acid combined with thalidomide had a higher risk of renal dys-
function (23). All of these drugs could induce renal dysfunction. 
Therefore, a maintenance treatment using these drug combina-
tions may play a major role in the renal dysfunction observed in 
patients treated with auto-HSCT. In this study, subgroup analy-
sis by maintenance therapy did not show a difference in evolu-
tion of renal function, because most patients who underwent 
auto-HSCT received maintenance therapy. To overcome this, 
studies are required to observe more patients.
  The association between renal dysfunction and TBI has been 
recognized for over a decade and was confirmed in some stud-
ies (24, 25). This typically occurs 6 to 12 months after the start of 
TBI. Although the primary site of radiation injury has not been 
identified, TBI is toxic to arteriole, glomerulaus and tubular epi-
thelium (24, 25). In addition, the cortical tubular damage follows 
from the vascular alterations caused by irradiation, leading to 
glomerulosclerosis (25). In our study, the half of patients who 
underwent auto-HSCT received TBI. This study shows that there 
was a significant decrease in the eGFR between the first and the 
twelfth month after the secondary HSCT in the patients who 
received TBI.
  In contrast with the results for auto-HSCT, the eGFR after allo-
HSCT decreased rapidly from the time of a secondary HSCT un-
til a month later, and it was then sustained up to 6 months after 
the secondary HSCT. Twelve months after allo-HSCT, the eGFR 
recovered and reached the level observed prior to HSCT. We 
think that this pattern of the eGFR variation could be attributed 
to calcineurin inhibitors and CMV infection. The calcineurin 
inhibitor and CMV infection are associated with a reduction in 
renal function (26). This is attributed to an indirect effect of CMV, 
which causes endothelial dysfunction and subsequent glomer-
ular impairment. In addition, calcineurin inhibitors used as pro-
phylaxis for, or as treatment of, GVHD are associated with renal 
dysfunction (26). Considering the higher dose of calcineurin 
inhibitor used in the early period after HSCT, this is a possible 
cause of renal dysfunction. 
  Fludarabine is a purine analogue and a component of reduced 
intensity conditioning regimens (27). We think that the initial de-Kang SH, et al.  •  Renal Function after Tandem HSCT
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cline of the eGFR might not be due to this drug, because renal 
toxicity of fludarabine occurs in less than 5% of patients. There 
are few studies on the decline of renal function caused by GVHD. 
To date, GVHD has usually been related to glomerular diseases, 
especially membranous nephropathy and minimal change dis-
ease; therefore, it seems unlikely that GVHD is associated with 
renal dysfunction (28).
  Some studies have shown HSCT performed in patients with 
multiple myeloma reversed renal failure (4, 29). A study showed 
that the development of dialysis-dependent renal failure in pa-
tients with myeloma can be reversed by HSCT after high levels 
of chemotherapy (29). Lee et al. demonstrated a dialysis dura-
tion  ≤ 6 months prior to HSCT and a pretransplant creatinine 
clearance of  > 10 mL/min were significant factors for renal 
function recovery (29). One patient excluded from our study 
underwent hemodialysis for 8 months prior to HSCT and renal 
failure was not reversed by HSCT.
  Our study had an inherent limitation of a retrospective analy-
sis and a small number of patients. Additionally, there was no 
significant difference in the two groups, but the trend showed a 
higher use of antibiotics or antifungal agents in auto-HSCT. These 
might be associated with the decline of renal function. Consid-
ering the rarity of the patients with tandem HSCT and many con-
founding factors associated with changes in renal function, pro-
spective multi-center study with more patients to control for vari-
ables is required.
  In summary, changes in eGFR varied according to the donor 
of HSCT. The eGFR recorded after allo-HSCT decreased rapidly 
from the time of HSCT until a month after the HSCT; subse-
quently, the eGFR recovered. The eGFR after auto-HSCT de-
creased slowly until the twelfth month after a secondary HSCT. 
This difference may be due to TBI, a calcineurin inhibitor, or 
maintemance therapy. Therefore, changes in renal function 
would be monitored closely for these patients. Just as the recov-
ery of the eGFR will be a main focus on the patients treated with 
TBI or a calcineurin inhibitor, a progressive decline of the eGFR 
will be also crucial for the patients treated with maintenance 
therapy. 
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There are few reports on the alteration of kidney function (estimated glomerular filtration rate [eGFR]) in multiple myeloma 
patients according to type of tandem hematopoietic stem cell transplantation (HSCT). In the auto-HSCT group (n = 20), the eGFR 
was significantly decrease. In contrast, the eGFR after allo-HSCT (n = 21) decreased initially, and then showed recovering tendency 
after 6 months of HSCT. This difference may be due to total body irradiation (TBI), calcineurin inhibitor, or maintemance therapy. 
It is requested to closely monitor the renal functions in those patients.